2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-153971
    URAT1 inhibitor 8 1632005-33-4 98.08%
    URAT1 inhibitor 8 (example 247) is a potent URAT1 inhibitor, with an IC50 of 0.001 μM. URAT1 inhibitor 8 can be used for gout research.
    URAT1 inhibitor 8
  • HY-155538
    Cisd2 agonist 1 2916371-54-3 99.22%
    Cisd2 agonist 1 (Compound 4q) is a Cisd2 agonist (EC50: 34 nM). Cisd2 agonist 1 enhances the Cisd2 expression and improves the pathological changes in the fatty livers. Cisd2 agonist 1 has good metabolic stability. Cisd2 agonist 1 can be used for research of NAFLD.
    Cisd2 agonist 1
  • HY-156277
    SP4f 3086376-13-5 99.77%
    SP4f is an activator ofPPAR-γ, with the EC50 of 826 nM in HK-2 cells. SP4f reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice.
    SP4f
  • HY-15790H
    (S)-Elobixibat 439087-68-0 98.75%
    (S)-Elobixibat is the S enantiomer of Elobixibat (HY-15790). (S)-Elobixibat is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor. (S)-Elobixibat decreases LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to study metabolic syndrome. (S)-Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.
    (S)-Elobixibat
  • HY-158000
    Bile acid probe 1 2148335-01-5 98.02%
    Bile acid probe 1, a clickable and photoreactive probe for Bile acid, contains ester linkage.
    Bile acid probe 1
  • HY-158584
    13-OAHSA 1997286-67-5 99.00%
    13-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-OAHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration.
    13-OAHSA
  • HY-15985A
    CTX-0294885 hydrochloride 2319590-02-6 99.73%
    CTX-0294885 hydrochloride is a broad spectrum kinase inhibitor that can capture 235 kinases from MDA-MB-231 cells, and can capture all members of the AKT family. CTX-0294885 hydrochloride is a powerful reagent for analysis of kinome signaling networks that can be used for the research of diseases like inflammation, diabetes, and cancer.
    CTX-0294885 hydrochloride
  • HY-159944
    PPARγ agonist 14 6951-57-1 98.0%
    PPARγ agonist 14 (compound 3) is a PPARy agonist (EC50=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases.
    PPARγ agonist 14
  • HY-159978
    EOS789 1628848-73-6 99.14%
    EOS789 is an orally active sodium-dependent phosphate transporter inhibitor, with IC50 values of 6.8, 1.5, and 1.7 μM against human NaPi-IIb, PiT-1, PiT-2, respectively; and IC50 values of 3.9, 1.9, and 1.7 μM against rat NaPi-IIb, PiT-1, PiT-2, respectively. EOS789 inhibits intestinal phosphate absorption, increases fecal phosphate excretion, reduces urinary phosphate excretion, and decreases the levels of serum phosphate, FGF23, and adult parathyroid hormone. EOS789 ameliorates ectopic thoracic aortic calcification, renal injury and hyperphosphatemia, and inhibits the expression of fibrosis markers. EOS789 can be used for the research of hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD).
    EOS789
  • HY-161781
    HVH-2930 3034605-72-3
    HVH-2930 is a HSP90 C-terminal domain inhibitor with high oral bioavailability. HVH-2930 downregulates HSP90 client proteins, inhibits the HER2 signaling pathway, induces apoptosis, and suppresses the proliferation of breast cancer cells. HVH-2930 inhibits the proliferation of tumors sensitive or resistant to Trastuzumab (HY-P9907). HVH-2930 is applicable to relevant research on breast cancer.
    HVH-2930
  • HY-162016
    IP6K-IN-1 3055440-67-7 99.37%
    IP6K-IN-1 (compound 24) is a potent and selective inhibitor of IP6K with an IC50 of 0.896 μM. IP6K-IN-1 can used in study metabolic disease.
    IP6K-IN-1
  • HY-162286
    α-Glucosidase-IN-50 98%
    α-Glucosidase-IN-50 (compound 8) is an inhibitor of α-Glucosidase.
    α-Glucosidase-IN-50
  • HY-162287
    α-Glucosidase-IN-51 98%
    α-Glucosidase-IN-51 (compound 9) is an inhibitor of α-Glucosidase.
    α-Glucosidase-IN-51
  • HY-164147
    Somapacitan 1338578-34-9
    Somapacitan is a growth hormone analog. Somapacitan is used for research on growth hormone deficiency.
    Somapacitan
  • HY-168376
    9(10)-Nitrooleate 1092676-99-7 99.0%
    9 (10)-Nitrooleate (9(10)-Nitrated oleic acid) is an endogenous lipid signaling mediator with vasoprotective effects. 9 (10)-Nitrooleate enhances enzymatic activity and improves nitric oxide bioavailability by inducing phosphorylation of Akt and ERK1/2, regulating the multi-site phosphorylation status of eNOS and optimizing its interaction with Hsp90. 9 (10)-Nitrooleate also activates PPARα, PPARδ and PPARγ receptors, thereby regulating adipogenesis, glucose uptake and inflammation-related gene expression, and exhibits immunosuppressive effects by inhibiting neutrophil migration and cytokine secretion. 9 (10)-Nitrooleate is widely used in studies of sepsis and related inflammatory diseases.
    9(10)-Nitrooleate
  • HY-169294
    SLC6A8 corrector 1 99.94%
    SLC6A8 corrector 1 is an orally active and brain-penetrant mutant SLC6A8 variant corrector. SLC6A8 corrector 1 can be used for the study of creatine transporter deficiency (CTD).
    SLC6A8 corrector 1
  • HY-16938S
    5'-Methylthioadenosine-13C6 2421187-73-5 98.45%
    5'-Methylthioadenosine-13C6 is the 13C-labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
    5'-Methylthioadenosine-13C6
  • HY-169792
    HPG1860 2226133-29-3 99.9%
    HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC50 of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC50 values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH).
    HPG1860
  • HY-170781
    MDI-114215 3099003-91-2 99.29%
    MDI-114215 (compound 85) is an allosteric LIMK1/2 dual inhibitor with good in vivo tolerance. MDI-114215 can inhibit cofilin phosphorylation in mouse brain region-induced pluripotent stem cells (iPSCs), which can be used for Fragile X Syndrome (FXS) research.
    MDI-114215
  • HY-171562
    Cholesterol-SA-PEG2000-Azide
    Cholesterol-SA-PEG2000-Azide is a lipid that can be used for drug delivery. Cholesterol-SA-PEG2000-Azide contains Cholesterol (HY-N0322), Succinic acid (HY-N0420), PEG units and an azide group. Cholesterol-SA-PEG2000-Azide contains an azide group that can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing an alkyne group.
    Cholesterol-SA-PEG2000-Azide
Cat. No. Product Name / Synonyms Application Reactivity